This is the authors' abstract. We don't add key points for this paper.
CLINICAL observations have recently been reported on the use of Cafergone, a new anticephalalgic agent for oral use consisting of 1 mg. of ergotamine tartrate and 100 mg. caffeine alkaloid. Several observers1 2 3 4 5 6 reported excellent results with Cafergone orally in vascular headache, and it was the consensus of most that Cafergone is effective in the treatment of migraine, especially when taken early and in adequate dosage, and that it is also of value in combating psychogenic headache. The results were especially encouraging in headache caused by overindulgence, as well as in that associated with fever and photophobia.In patients in whom . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Arnold H. Kadish (1950) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: